Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer

Cancer Research

Volumn 63, Issue 15, 2003, Pages 4698-4704

  Xiao, Wuhan ^a   Zhang, Qiuheng ^a   Jiang, Feng ^a   Pins, Michael ^a   Kozlowski, James M ^a   Wang, Zhou ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PROTEIN; TESTOSTERONE; U19 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; GENE DELETION; GENE DISRUPTION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HORMONE ACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TUMOR GROWTH; XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NANDROLONE; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0041633811     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Ross, R. K., Pike, M. C., Coetzee, G. A., Reichardt, J, K., Yu, M. C., Feigelson, H., Stanczyk, F. Z., Kolonel, L. N., and Henderson, B. E, Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res., 58: 4497-4504, 1998.
2. Pollard, M. Lobund-Wistar rat model of prostate cancer in man. Prostate, 37: 1-4, 1998.
3. Noble, R. L. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res., 37: 1929-1933, 1977.
4. Dai, W. S., Kuller, L. H., LaPorte, R. E., Gutai, J. P., Falvo-Gerard, L., and Caggiula, A. The epidemiology of plasma testosterone levels in middle-aged men. Am. J. Epidemiol., 114: 804-816, 1981.
5. Sternbach, H. Age-associated testosterone decline in men: clinical issues for psychiatry. Am. J. Psychiatry, 155: 1310-1318, 1998.
6. Morley, J. E., Kaiser, F. E., Perry, H. M., III, Patrick, P., Morley, P. M., Stauber, P. M., Vellas, B., Baumgartner, R. N., and Garry, P. J. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism, 46: 410-413, 1997.
7. English, H, F., Kyprianou, N., and Isaacs, J. T. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate, 15: 233-250, 1989.
8. Bruchovsky, N., Lesser, B., Doorn, E. V., and Craven, S. Hormonal effects on cell proliferation in rat prostate. Vitam. Horm., 33: 61-102, 1975.
9. Zhou, Z., Wong, C., Sar, M., and Wilson, E. The androgen receptor: an overview. Recent Prog. Horm. Res., 49: 249-274, 1994.
10. Wang, Z., Tufts, R., Haleem, R., and Cai, X. Genes regulated by androgen in the rat ventral prostate. Proc. Natl. Acad. Sci. USA, 94: 12999-13004, 1997.
11. Zhu, N., and Wang, Z. An assay for DNA fragmentation in apoptosis without phenol/chloroform extraction and ethanol precipitation. Anal. Biochem., 246: 155-158, 1997.
12. Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu Y., Lalla, E., Fu, C., Hofmann, M. A., Kislinger, T., Ingram, M., Lu, A., Tanaka, H. Hori, O., Ogawa, S., Stern, D. M., and Schmidt, A. M. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (Lond.), 405: 354-360, 2000.
13. Zhu, N., and Wang, Z. Calreticulin expression is associated with androgen regulation of the sensitivity to calcium ionophore-induced apoptosis in LNCaP prostate cancer cells. Cancer Res., 59: 1896-1902, 1999.
14. Narla, G., Heath, K. E., Reeves, H. L., Li, D., Giono, L. E., Kimmelman, A. C. Glucksman, M. J., Narla, J., Eng, F. J., Chan, A. M., Ferrari, A. C., Martignetti, J. A. and Friedman, S. L. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science (Wash. DC), 294: 2563-2566, 2001.
15. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
16. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M. Mirand, E. A., and Murphy, G. P. LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.
17. Kaighn, M. E., Narayan, K. S., Ohnuki, Y., Lechner, J. F., and Jones, L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investig. Urol., 17: 16-23, 1979.
18. Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H., and Paulson, D. F. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer, 21: 274-281, 1978.
19. Iizumi, T., Yazaki, T., Kanoh, S., Kondo, I., and Koiso, K. Establishment of a new prostatic carcinoma cell line (TSU-Prl). J. Urol., 137: 1304-1306, 1987.
20. Isaacs, J. T., Isaacs, W. B., Feitz, W. F., and Scheres, J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate, 9: 261-281, 1986.
21. Littlewood, T. D., Hancock, D. C., Danielian, P. S., Parker, M. G., and Evan, G. I. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res., 23: 1686-1690, 1995.
22. Sengupta, S., Ralhan, R., and Wasylyk, B. Tumour regression in a ligand inducible manner mediated by a chimeric tumour suppressor derived from p53. Oncogene, 19: 337-350, 2000.
23. Shevrin, D. H., Gorny, K. I., and Kukreja, S. C. Patterns of metastasis by the human prostate cancer cell line PC-3 in athymic nude mice. Prostate, 15: 187-194, 1989.
24. Kimura, K., Markowski, M., Bowen, C., and Gelmann, E. P. Androgen blocks apoptosis of hormone-dependent prostate cancer cells. Cancer Res., 61: 5611-5618, 2001.
25. Hugel, A., and Wernert, N. Loss of heterozygosity (LOH), malignancy grade and clonality in microdissected prostate cancer. Br. J. Cancer, 79: 551-557, 1999.
26. Ittmann, M. M., and Wieczorek, R. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum. Pathol., 27: 28-34, 1996
27. Bookstein, R., Rio, P., Madreperla, S. A., Hong, F., Allred, C., Grizzle, W. E., and Lee, W. H. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc. Natl. Acad. Sci. USA, 87: 7762-7766, 1990.
28. Brooks, J. D., Bova, G. S., Ewing, C. M., Piantadosi, S., Carter, B. S., Robinson, J. C., Epstein, J. I., and Isaacs, W. B. An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res., 56: 3814-3822, 1996.
29. Macera, M. J., Godec, C. J., Sharma, N., and Verma, R. S. Loss of heterozygosity of the TP53 tumor suppressor gene and detection of point mutations by the non-isotopic RNAse cleavage assay in prostate cancer. Cancer Genet. Cytogenet., 108: 42-47, 1999.
30. Massenkeil, G., Oberhuber, H., Hailemariam, S., Sulser, T., Diener, P. A., Bannwart, F., Schafer, R., and Schwarte-Waldhoff, I. P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer. Anticancer Res., 14: 2785-2790, 1994.
31. Leube, B., Drechsler, M., Muhlmann, K., Schafer, R., Schulz, W. A., Santourlidis, S., Anastasiadis, A., Ackermann, R., Visakorpi, T., Muller, W., and Royer-Pokora, B. Refined mapping of allele loss at chromosome 10q23-26 in prostate cancer. Prostate, 50: 135-144, 2002.
32. Abate-Shen, C., and Shen, M. M. Molecular genetics of prostate cancer. Genes Dev., 14: 2410-2434, 2000.
33. Simone, F., Polak, P. E., Kaberlein, J. J., Luo, R. T., Levitan, D. A., and Thirman, M. J. EAF1, a novel ELL-associated factor that is delocalized by expression of the MLL-ELL fusion protein. Blood, 98: 201-209, 2001.
34. Simone, F., Luo, R. T., Polak, P. E., Kaberlein, J. J., and Thirman, M. J. ELL-associated factor 2 (EAF2), a functional homologue of EAF1 with alternative ELL binding properties. Blood, 101: 2355-2362, 2003.